Denali Therapeutics Inc (DNLI) Stock Price, Quote & News

Company Profile

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; DNL343 eIF2B activator program for amyotrophic lateral sclerosis; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Synd...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 866 8547

Website: www.denalitherapeutics.com

Address:

161 Oyster Point Boulevard, South San Francisco, United States

Daddy044 Jan. 29 at 12:32 PM

$IMMX A friend just told me about a Jeffries report that claimed approximately 72% of drugs with Breakthrough. The remaining roughly 43% fail because of missed primary endpoints not regulatory rejection. Names to watch include $IMMX, $BIIB, $BBIO, $DNLI, $AKRO (sold), $DYN $STOK $PRAX is a precision neuro trio.

1 · Reply

BullDonald Jan. 29 at 12:53 AM

$DNLI $30 is brewing ! here.

0 · Reply

BullDonald Jan. 28 at 9:56 PM

$DNLI Planning on Averaging UP again $VNDA Planning on Averaging UP again $ETON Hold $NRXP Watching

0 · Reply

Longbuy1 Jan. 28 at 6:29 PM

$DNLI $RGNX it's saying that retail is stupid and sell your shares cheap,.

0 · Reply

Longbuy1 Jan. 28 at 6:04 PM

$DNLI $RGNX DNL310 is in phase 2\3, screw your paid written article.

0 · Reply

prismmarketview Jan. 28 at 5:54 PM

An FDA review delay and new safety overhang for Regenxbio’s (NASDAQ: $RGNX) RGX‑121 in Hunter syndrome are giving Denali’s Denali Therapeutics (NASDAQ: $DNLI) tividenofusp alfa a clearer shot at first‑to‑market status in this rare‑disease race. https://prismmarketview.com/fda-delay-for-regenxbio-may-open-the-door-for-denali-in-hunter-syndrome-race/

1 · Reply

dgbio Jan. 28 at 5:41 PM

$DNLI Clinical hold on a somewhat competing product from Regenxbio should be seen as a somewhat positive for Denali. The difference in delivery mechanisms, AAV vector vs ERT, means no spillover impact on Denali's product.

0 · Reply

S_Franconi Jan. 28 at 3:26 PM

$DNLI $IVA $CTMX

0 · Reply

lebranjames Jan. 28 at 12:41 PM

$DNLI take notes 📝 can’t afford a CRL like $RGNX

0 · Reply

BullDonald Jan. 26 at 1:39 PM

$DNLI we will see a move towards $30 here.

0 · Reply

Denali Therapeutics Inc. (DNLI) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Dec 30, 2025, 8:00 AM EST - 4 weeks ago

The New England Journal of Medicine Publishes Phase 1/2 Study of Denali Therapeutics' Tividenofusp Alfa (DNL310) for Hunter Syndrome (MPS II)

Dec 10, 2025, 2:47 PM EST - 7 weeks ago

Denali: Maintaining Strong Buy Based On DNL126 Expansion As MPS IIIA Treatment

Dec 10, 2025, 12:14 AM EST - 7 weeks ago

Denali Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

Dec 9, 2025, 4:01 PM EST - 7 weeks ago

Denali Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants

Dec 5, 2025, 2:58 AM EST - 7 weeks ago

Denali Therapeutics Inc. (DNLI) Analyst/Investor Day Transcript

Dec 4, 2025, 7:00 AM EST - 2 months ago

Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement

RPRX

Dec 2, 2025, 8:09 AM EST - 2 months ago

Denali: Regulatory Delay Is A Strategic Opportunity

Nov 22, 2025, 3:03 AM EST - 2 months ago

Denali Therapeutics Inc. (DNLI) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov 6, 2025, 4:01 PM EST - 2 months ago

Denali Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights

Oct 14, 2025, 2:43 PM EDT - 3 months ago

FDA Delays Decision Date For Denali Therapeutics' Lead Drug Candidate

Oct 13, 2025, 4:01 PM EDT - 3 months ago

Denali Therapeutics Announces FDA Review Extension of BLA for Tividenofusp Alfa for the Treatment of MPS II (Hunter Syndrome)

Sep 9, 2025, 2:31 AM EDT - 5 months ago

Denali Therapeutics Inc. (DNLI) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Aug 12, 2025, 9:47 AM EDT - 6 months ago

The Best Small-Cap Stocks to Buy Now

KYMR WAY

Aug 11, 2025, 4:01 PM EDT - 6 months ago

Denali Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights

Jul 7, 2025, 8:00 AM EDT - 7 months ago

Denali Therapeutics Announces FDA Acceptance and Priority Review of Biologics License Application (BLA) for Tividenofusp Alfa for Hunter Syndrome (MPS II)

May 6, 2025, 4:01 PM EDT - 9 months ago

Denali Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights Including Completion of BLA Rolling Submission for Tividenofusp Alfa for Hunter Syndrome

Apr 2, 2025, 8:00 AM EDT - 10 months ago

Denali Therapeutics Announces Initiation of BLA Filing for Accelerated Approval of Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) and Positive Ongoing Interactions with FDA on DNL126 Through START Program

Mar 27, 2025, 7:40 AM EDT - 11 months ago

Biotech stocks have been hit hard. Why they're a great value now.

PFE BHVN GPCR INSM MRK SWTX

Mar 20, 2025, 2:16 PM EDT - 11 months ago

Denali Therapeutics: Vast Pipeline, First Approval Up Ahead

Feb 27, 2025, 4:01 PM EST - 11 months ago

Denali Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

Feb 6, 2025, 11:42 AM EST - 1 year ago

Denali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp Alfa

Jan 15, 2025, 2:26 PM EST - 1 year ago

Why Is Denali Therapeutics Stock Trading Higher On Wednesday?

Jan 9, 2025, 3:56 PM EST - 1 year ago

Denali: Despite ALS Primary Endpoint Failure, Possible Path Forward Remains

Jan 6, 2025, 4:43 PM EST - 1 year ago

Denali Therapeutics ALS drug fails in mid-stage trial

Jan 6, 2025, 4:30 PM EST - 1 year ago

Denali Therapeutics Announces Topline Results for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial

Jan 3, 2025, 1:08 PM EST - 1 year ago

Denali Therapeutics Neurodegenerative Disease Platform Sparks Analyst Optimistic

Nov 16, 2024, 8:56 AM EST - 1 year ago

Denali Has A Neurodegenerative Edge Despite Market Skepticism

Nov 6, 2024, 4:01 PM EST - 1 year ago

Denali Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights

Sep 3, 2024, 8:00 AM EDT - 1 year ago

Denali Therapeutics Announces Successful Meeting with the FDA and Plans to File for Accelerated Approval of Tividenofusp Alfa (DNL310) for the Treatment of MPS II (Hunter Syndrome)

Aug 19, 2024, 10:55 PM EDT - 1 year ago

Denali Therapeutics: A Promising Biotech With Revolutionary BBB-Crossing Technology

Aug 14, 2024, 2:00 PM EDT - 1 year ago

Denali Therapeutics Announces Publication in Science Translational Medicine Demonstrating the Potential of the Oligonucleotide Transport Vehicle Platform to Achieve Broad Biodistribution of Antisense Oligonucleotides in the CNS and Muscle Following Intravenous Administration

Aug 1, 2024, 6:45 AM EDT - 1 year ago

Denali Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights

Jun 3, 2024, 8:00 AM EDT - 1 year ago

Denali Therapeutics Announces FDA Has Selected DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo Syndrome Type A) for START Pilot Program Intended to Accelerate Development of Rare Disease Therapies

May 13, 2024, 12:30 PM EDT - 1 year ago

Denali Therapeutics: MPS Treatment Program Continues With End Of 2024 Data

May 7, 2024, 4:01 PM EDT - 1 year ago

Denali Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights

May 1, 2024, 8:00 AM EDT - 1 year ago

Denali Therapeutics Announces Completion of Enrollment for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial

Mar 6, 2024, 10:05 PM EST - 2 years ago

Denali: Leveraging Transport Vehicle Technology For Neurological Gains

Feb 27, 2024, 8:05 AM EST - 2 years ago

Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

Feb 27, 2024, 8:00 AM EST - 2 years ago

Denali Therapeutics Announces $500 million Private Placement Equity Financing

Feb 7, 2024, 8:00 AM EST - 2 years ago

Denali Therapeutics Announces New Data and Expansion of Its Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapy Programs at WORLDSymposium™

Feb 1, 2024, 8:00 AM EST - 2 years ago

Denali Therapeutics Announces Presentations on Its Investigational Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapies at the Upcoming 2024 WORLDSymposium™

Jan 8, 2024, 8:00 AM EST - 2 years ago

Denali Therapeutics Announces Key Anticipated 2024 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases

Nov 7, 2023, 4:01 PM EST - 2 years ago

Denali Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights

Oct 2, 2023, 5:26 AM EDT - 2 years ago

Denali's New Summit: Changing Hunter Syndrome Landscape

Sep 11, 2023, 6:30 AM EDT - 2 years ago

Flagship Pioneering Announces Appointment of Amanda Kay as Chief Business Development Officer

FHTX MCRB MRNA SANA

Aug 30, 2023, 8:30 AM EDT - 2 years ago

Denali Therapeutics Announces New Interim Data from Phase 1/2 Study of DNL310 (ETV:IDS) in MPS II (Hunter Syndrome) at SSIEM 2023

Aug 8, 2023, 4:01 PM EDT - 2 years ago

Denali Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights

Jul 23, 2023, 12:51 AM EDT - 2 years ago

MPS II And Beyond: Implications Of Denali's Promising Pipeline

Jun 21, 2023, 6:00 AM EDT - 2 years ago

Flagship Pioneering Unveils Empress Therapeutics to Revolutionize Drug Discovery by Applying the Power of Genetics to Identify Small Molecule Drugs

FHTX MCRB MRNA SANA

Daddy044 Jan. 29 at 12:32 PM

1 · Reply

BullDonald Jan. 29 at 12:53 AM

$DNLI $30 is brewing ! here.

0 · Reply

BullDonald Jan. 28 at 9:56 PM

$DNLI Planning on Averaging UP again $VNDA Planning on Averaging UP again $ETON Hold $NRXP Watching

0 · Reply

Longbuy1 Jan. 28 at 6:29 PM

$DNLI $RGNX it's saying that retail is stupid and sell your shares cheap,.

0 · Reply

Longbuy1 Jan. 28 at 6:04 PM

$DNLI $RGNX DNL310 is in phase 2\3, screw your paid written article.

0 · Reply

prismmarketview Jan. 28 at 5:54 PM

1 · Reply

dgbio Jan. 28 at 5:41 PM

0 · Reply

S_Franconi Jan. 28 at 3:26 PM

$DNLI $IVA $CTMX

0 · Reply

lebranjames Jan. 28 at 12:41 PM

$DNLI take notes 📝 can’t afford a CRL like $RGNX

0 · Reply

BullDonald Jan. 26 at 1:39 PM

$DNLI we will see a move towards $30 here.

0 · Reply

onlyGreenPlz Jan. 25 at 8:09 AM

$DNLI Awaiting DNL310 PDUFA. Likely already priced in but looking for $30-35 range. Above that would be cherry on top.

0 · Reply

BullDonald Jan. 23 at 1:00 PM

$DNLI Did not expect it to move at this rate ... PT 30 is insight at this point.

0 · Reply

BullDonald Jan. 22 at 6:11 PM

$DNLI AVERAGED UP for the SECOND time Baby $ETON I need more of it. $VNDA I Love you too, AVERAGED UP Today $ESPR LOCO fiancials, No Touchy Touchy

0 · Reply

BullDonald Jan. 22 at 3:29 PM

$DNLI Just like that we are at $ 20 we will see $ 25 in weeks . Load the F up.

0 · Reply

topstockalerts Jan. 21 at 4:03 PM

$DNLI Primed for continuation with bulls in control 🐂. Buyers dominate the tape. This could keep running.

0 · Reply

BullDonald Jan. 21 at 3:58 PM

$DNLI Averaged UP Today , Go baby GO. $ETON ADDED Today, My Old love, she Will Fly soon $ESPR 👈 TRASH mode, LOCO board. would not touch it yet

0 · Reply

BullDonald Jan. 21 at 3:19 PM

$ETON 👈Still Need a Boost, sluggish, give it to me. $DNLI is flying ... Muito Bonita 🚀

0 · Reply

BullDonald Jan. 21 at 3:05 PM

$DNLI GO BABY GO 🚀

0 · Reply

BullDonald Jan. 18 at 4:35 PM

$DNLI I m considering Averaging Up. This is warmming up way long before Approval. At this rate Will blow pass 25

0 · Reply

S_Franconi Jan. 17 at 2:19 AM

$DNLI

0 · Reply

Teillbou Jan. 16 at 5:21 PM

$DNLI how does DNL310 for Hunter compare to genetic therapy regenxbio RGX-121. Wich one is better do you think ?

1 · Reply

BullDonald Jan. 13 at 10:01 PM

$DNLI LOAD the Truck.

0 · Reply

Market Cap	3.12B
Revenue (ttm)	0.00
Net Income (ttm)	-422.77M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	2,632,700
Avg Vol	1,619,518
Day's Range	N/A - N/A
Shares Out	146.66M
Stochastic %K	79%
Beta	1.05
Analysts	Strong Sell
Price Target	$32.86